Jacobus J Van Hilten

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5760179/publications.pdf

Version: 2024-02-01

54 papers

7,724 citations

218677 26 h-index 53 g-index

57 all docs 57 docs citations

57 times ranked

9544 citing authors

#	Article	IF	CITATIONS
1	Patient-Related Factors Influencing Caregiver Burden in Parkinson's Disease Patients: Comparison of Effects Before and After Deep Brain Stimulation. Journal of Parkinson's Disease, 2022, , 1-9.	2.8	2
2	Assessing walking adaptability in stroke patients. Disability and Rehabilitation, 2021, 43, 3242-3250.	1.8	8
3	Differences in the Presentation and Progression of Parkinson's Disease by Sex. Movement Disorders, 2021, 36, 106-117.	3.9	54
4	Experience in Genetic Counseling for GBA1 Variants in Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 33-36.	1.5	5
5	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. Journal of Parkinson's Disease, 2021, 11, 395-404.	2.8	56
6	Cingulate networks associated with gray matter loss in Parkinson's disease show high expression of cholinergic genes in the healthy brain. European Journal of Neuroscience, 2021, 53, 3727-3739.	2.6	5
7	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	5.3	29
8	Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. Nature Genetics, 2021, 53, 787-793.	21.4	82
9	Preoperative Electroencephalographyâ€Based Machine Learning Predicts Cognitive Deterioration After Subthalamic Deep Brain Stimulation. Movement Disorders, 2021, 36, 2324-2334.	3.9	12
10	Transcriptomic Signatures Associated With Regional Cortical Thickness Changes in Parkinson's Disease. Frontiers in Neuroscience, 2021, 15, 733501.	2.8	2
11	Holocue: A Wearable Holographic Cueing Application for Alleviating Freezing of Gait in Parkinson's Disease. Frontiers in Neurology, 2021, 12, 628388.	2.4	9
12	Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. Brain, 2020, 143, 234-248.	7.6	149
13	Effect of deep brain stimulation on caregivers of patients with Parkinson's disease: A systematic review. Parkinsonism and Related Disorders, 2020, 81, 20-27.	2.2	13
14	Transcriptomic signatures of brain regional vulnerability to Parkinson's disease. Communications Biology, 2020, 3, 101.	4.4	58
15	Fecal Microbiota Transplantation in Neurological Disorders. Frontiers in Cellular and Infection Microbiology, 2020, 10, 98.	3.9	221
16	A <scp>Largeâ€Scale</scp> Full <scp><i>GBA1</i></scp> Gene Screening in Parkinson's Disease in the Netherlands. Movement Disorders, 2020, 35, 1667-1674.	3.9	41
17	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. Movement Disorders, 2019, 34, 1839-1850.	3.9	122
18	Studying reproducibility of data-driven Parkinson's disease subtypes. Parkinsonism and Related Disorders, 2019, 62, 251-252.	2.2	1

#	Article	IF	CITATIONS
19	Regional Structural Hippocampal Differences Between Dementia with Lewy Bodies and Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, 775-783.	2.8	8
20	Peripheral mitochondrial function correlates with clinical severity in idiopathic Parkinson's disease. Movement Disorders, 2019, 34, 1192-1202.	3.9	23
21	Age- and disease-related cerebral white matter changes in patients with Parkinson's disease. Neurobiology of Aging, 2019, 80, 203-209.	3.1	31
22	Parkinson's disease age at onset genomeâ€wide association study: Defining heritability, genetic loci, and αâ€synuclein mechanisms. Movement Disorders, 2019, 34, 866-875.	3.9	258
23	Walking adaptability for targeted fall-risk assessments. Gait and Posture, 2019, 70, 203-210.	1.4	29
24	Sex matters in complex regional pain syndrome. European Journal of Pain, 2019, 23, 1108-1116.	2.8	12
25	Risk factors for non-motor symptoms in Parkinson's disease. Lancet Neurology, The, 2018, 17, 559-568.	10.2	225
26	Does deep brain stimulation of the subthalamic nucleus prolong survival in Parkinson's Disease?. Movement Disorders, 2018, 33, 947-949.	3.9	8
27	Assessing Walking Adaptability in Parkinson's Disease: "The Interactive Walkway― Frontiers in Neurology, 2018, 9, 1096.	2.4	21
28	Clinical correlates of quantitative EEG in Parkinson disease. Neurology, 2018, 91, 871-883.	1.1	112
29	Cognitiveâ€motor interference during goalâ€directed upperâ€limb movements. European Journal of Neuroscience, 2018, 48, 3146-3158.	2.6	24
30	Quantitative EEG reflects non-dopaminergic disease severity in Parkinson's disease. Clinical Neurophysiology, 2018, 129, 1748-1755.	1.5	23
31	Oral Health of Parkinson's Disease Patients: A Case-Control Study. Parkinson's Disease, 2018, 2018, 1-8.	1.1	33
32	Altered Whole-Brain and Network-Based Functional Connectivity in Parkinson's Disease. Frontiers in Neurology, 2018, 9, 419.	2.4	51
33	The terminology of akinesia, bradykinesia and hypokinesia: Past, present and future. Parkinsonism and Related Disorders, 2017, 37, 27-35.	2.2	34
34	A post hoc study on gene panel analysis for the diagnosis of dystonia. Movement Disorders, 2017, 32, 569-575.	3.9	59
35	Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts. Lancet Neurology, The, 2017, 16, 620-629.	10.2	131
36	Loss of integrity and atrophy in cingulate structural covariance networks in Parkinson's disease. NeuroImage: Clinical, 2017, 15, 587-593.	2.7	32

#	Article	IF	CITATIONS
37	Postural instability and gait are associated with severity and prognosis of Parkinson disease. Neurology, 2016, 86, 2243-2250.	1.1	78
38	Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease. Movement Disorders, 2016, 31, 1408-1413.	3.9	55
39	Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. Annals of Neurology, 2016, 80, 674-685.	5.3	226
40	The course of insomnia in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 33, 51-57.	2.2	52
41	Associated and predictive factors of depressive symptoms in patients with Parkinson's disease. Journal of Neurology, 2016, 263, 1215-1225.	3.6	25
42	Course and risk factors for excessive daytime sleepiness in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 24, 34-40.	2.2	70
43	Evaluation of severity of predominantly non-dopaminergic symptoms in Parkinson's disease: The SENS-PD scale. Parkinsonism and Related Disorders, 2016, 25, 39-44.	2.2	16
44	Diurnal and Nocturnal Skin Temperature Regulation in Chronic Complex Regional Pain Syndrome. Journal of Pain, 2015, 16, 207-213.	1.4	4
45	Motor Cortical Activity During Motor Tasks Is Normal in Patients With Complex Regional Pain Syndrome. Journal of Pain, 2015, 16, 87-94.	1.4	10
46	Evaluation of mirrored muscle activity in patients with Complex Regional Pain Syndrome. Clinical Neurophysiology, 2014, 125, 2100-2108.	1.5	4
47	Intense Pain Soon After Wrist Fracture Strongly Predicts Who Will Develop Complex Regional Pain Syndrome: Prospective Cohort Study. Journal of Pain, 2014, 15, 16-23.	1.4	125
48	Calculating clinical progression rates in Parkinson's disease: Methods matter. Parkinsonism and Related Disorders, 2014, 20, 1263-1267.	2.2	13
49	Predictors of dementia in Parkinson's disease; findings from a 5-year prospective study using the SCOPA-COG. Parkinsonism and Related Disorders, 2014, 20, 980-985.	2.2	98
50	Survival in Parkinson's disease. Relation with motor and non-motor features. Parkinsonism and Related Disorders, 2014, 20, 613-616.	2.2	62
51	Movement Disorders in Complex Regional Pain Syndrome. Pain Medicine, 2010, 11, 1274-1277.	1.9	63
52	Reply: Myoclonus in complex regional pain syndrome. Movement Disorders, 2009, 24, 316-316.	3.9	25
53	Movement Disorder Societyâ€sponsored revision of the Unified Parkinson's Disease Rating Scale (MDSâ€UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 2008, 23, 2129-2170.	3.9	4,796
54	Peripheral trauma and movement disorders. Parkinsonism and Related Disorders, 2007, 13, S395-S399.	2.2	17